EGFR and neoplasm: Another mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, blocks the EGFRL858R/T790M/C797S signaling both in vitro and in vivo and has antitumor activity against an NSCLC xenograft tumor [85].